1832 Asset Management L.P. Blueprint Medicines Corp Transaction History

1832 Asset Management L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$85.18 - $108.78 $42.8 Million - $54.7 Million	502,400 Added 200159.36%	502,651 $54.2 Million
Q3 2023 Nov 13, 2023	BUY	$46.9 - $66.0 $11,771 - $16,566	251 New	251 $12,000
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $13,579 - $27,630	251 New	251 $16,000
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $1.76 Million - $2.44 Million	-24,100 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $1.77 Million - $2.36 Million	24,100 New	24,100 $2.24 Million
Q2 2018 Aug 14, 2018	SELL	$60.96 - $101.18 $1.01 Million - $1.67 Million	-16,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $1.21 Million - $1.7 Million	16,500 New	16,500 $1.52 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on 1832 Asset Management L.P. with notifications on news.